Dec 17 (Reuters) - HedgePath Pharmaceuticals Inc HPPI.PK :
* HEDGEPATH PHARMACEUTICALS AND MAYNE PHARMA ENTER INTO UPDATED COLLABORATION AND FUNDING AGREEMENTS
* UNDER NEW SLA, CO WILL ASSUME CONTROL OF REGULATORY AND CLINICAL DEVELOPMENT PROGRAM FOR SUBA-ITRACONAZOLE
* TO TRANSFER SUBA-ITRACONAZOLE BCCNS CLINICAL PROGRAM TO MAYNE IN CONSIDERATION OF UP TO $5 MILLION IN NEW FUNDING FROM MAYNE
* WILL IMMEDIATELY ASSUME RESPONSIBILITY FOR ALL FUTURE SUBA-ITRACONAZOLE BCCNS-RELATED EXPENSES
* WITH NEW FUNDING, CO TO MOVE TOWARDS IND FILING DURING 2019 & RECRUITMENT TO INITIATE HUMAN TRIALS FOR SUBA-ITRACONAZOLE PROSTATE
* CO TO RECEIVE 9% ROYALTY ON FUTURE NET SALES OF SUBA-ITRACONAZOLE BCCNS IN U.S.